Grifols | GRFS - Interest Expense On Debt

Stock Price
8.08
Daily Change
0.09 1.13%
Monthly
4.80%
Yearly
12.07%
Q2 Forecast
7.87

Grifols reported EUR156.07M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Arca Biopharma USD 504K 246K Sep/2024
Bio Path 130K 95K Sep/2025
Capricor Therapeutics 3.05M 2.46M Dec/2025
Cara Therapeutics 39.02M 4.73M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Immunic 400K 400K Dec/2024
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
TherapeuticsMD USD 20K 25K Sep/2023